Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 54 Carcinoma, Hepatocellular 39 Carcinoma, Non-Small-Cell Lung 21 Small Cell Lung Carcinoma 18 Ovarian Neoplasms 17 Colorectal Neoplasms 15 Breast Neoplasms 13 Sarcoma 12 Triple Negative Breast Neoplasms 11 Nasopharyngeal Carcinoma 11 Neoplasms 10 Esophageal Squamous Cell Carcinoma 10 Esophageal Neoplasms 9 Cholangiocarcinoma 9 Neoplasm Metastasis 7 Lung Neoplasms 7 Advanced Gastric Cancer 7 Squamous Cell Carcinoma of Head and Neck 6 Recurrence 6 Osteosarcoma 6 Head and Neck Neoplasms 6 Biliary Tract Neoplasms 6 Uterine Cervical Neoplasms 5 Liver Neoplasms 5 Solid Tumor 4 Pancreatic Neoplasms 4 Melanoma 4 Glioma 4 Thyroid Neoplasms 3 NSCLC 3

Interventions

Paclitaxel 2 Etoposide 2 Carboplatin 2 sintilimab 1 atezolizumab 1 apatinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡